These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 6611553

  • 1. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain.
    Javitch JA, Uhl GR, Snyder SH.
    Proc Natl Acad Sci U S A; 1984 Jul; 81(14):4591-5. PubMed ID: 6611553
    [Abstract] [Full Text] [Related]

  • 2. Similar distribution of monoamine oxidase (MAO) and parkinsonian toxin (MPTP) binding sites in human brain.
    Reznikoff G, Manaker S, Parsons B, Rhodes CH, Rainbow TC.
    Neurology; 1985 Oct; 35(10):1415-9. PubMed ID: 3875804
    [Abstract] [Full Text] [Related]

  • 3. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.
    Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH.
    Proc Natl Acad Sci U S A; 1985 Apr; 82(7):2173-7. PubMed ID: 3872460
    [Abstract] [Full Text] [Related]

  • 4. Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]pargyline binding to monoamine oxidase.
    Rainbow TC, Parsons B, Wieczorek CM, Manaker S.
    Brain Res; 1985 Mar 25; 330(2):337-42. PubMed ID: 3872699
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD.
    Synapse; 1993 Jun 25; 14(2):184-94. PubMed ID: 8332947
    [Abstract] [Full Text] [Related]

  • 7. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate.
    Porrino LJ, Burns RS, Crane AM, Palombo E, Kopin IJ, Sokoloff L.
    Life Sci; 1987 Apr 27; 40(17):1657-64. PubMed ID: 3494179
    [Abstract] [Full Text] [Related]

  • 8. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA, Rothblat DS, Joyce JN, Schneider JS.
    Synapse; 1995 Jan 27; 19(1):46-55. PubMed ID: 7709343
    [Abstract] [Full Text] [Related]

  • 9. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW.
    Fortschr Neurol Psychiatr; 1989 Apr 27; 57(4):142-8. PubMed ID: 2656447
    [Abstract] [Full Text] [Related]

  • 10. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
    Miyoshi R, Kito S, Ishida H, Katayama S.
    Res Commun Chem Pathol Pharmacol; 1988 Oct 27; 62(1):93-102. PubMed ID: 2849789
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Neurotensin receptor binding sites in monkey and human brain: autoradiographic distribution and effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
    Quirion R, Welner S, Gauthier S, Bédard P.
    Synapse; 1987 Oct 27; 1(6):559-66. PubMed ID: 2843996
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Distribution of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in experimental animals studied by postiron emission tomography and whole body autoradiography.
    Hartvig P, Lindquist NG, Aquilonius SM, d'Argy R, Bergström K, Bondesson U, Eckernäs SA, Gullberg P, Larsson BS, Lindberg B.
    Life Sci; 1986 Jan 06; 38(1):89-97. PubMed ID: 3484535
    [Abstract] [Full Text] [Related]

  • 18. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
    Riachi NJ, Harik SI, Kalaria RN, Sayre LM.
    J Pharmacol Exp Ther; 1988 Feb 06; 244(2):443-8. PubMed ID: 3258032
    [Abstract] [Full Text] [Related]

  • 19. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey.
    Crossman AR, Mitchell IJ, Sambrook MA.
    Neuropharmacology; 1985 Jun 06; 24(6):587-91. PubMed ID: 3875056
    [Abstract] [Full Text] [Related]

  • 20. The dopamine neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset.
    Gibb WR, Lees AJ, Jenner P, Marsden CD.
    Neurosci Lett; 1986 Mar 28; 65(1):79-83. PubMed ID: 3486388
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.